Search results
Z51.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2025 edition of ICD-10-CM Z51.81 became effective on October 1, 2024. This is the American ICD-10-CM version of Z51.81 - other international versions of ICD-10 Z51.81 may differ.
- Z51.1
ICD 10 code for Encounter for antineoplastic chemotherapy...
- Monitoring
ICD-10-PCS; Female Only Procedure Codes; Male Only Procedure...
- Z52.011
Z52.011 is a billable/specific ICD-10-CM code that can be...
- Z79.634
Long term (current) use of topoisomerase inhibitor. 2023 -...
- Z51.1
20 gru 2014 · ABSTRACT. The current vancomycin therapeutic guidelines recommend the use of only trough concentrations to manage the dosing of adults with Staphylococcus aureus infections. Both vancomycin efficacy and toxicity are likely to be related to the area under the plasma concentration-time curve (AUC).
1 cze 2017 · Vancomycin-associated nephrotoxicity is linked with increased duration of hospitalization, costs, and risk of mortality. Elevated trough concentrations are associated with a higher incidence of nephrotoxicity, but not clinical cure. Monitoring vancomycin concentrations consumes time and resources.
Because guidelines have varied on optimal target trough levels, and the somewhat broad definition of trough used, elevated vancomycin levels were defined conservatively as trough levels >30 mg/L. A sensitivity analysis was conducted using a lower cutoff (>20 mg/L).
Peak levels should be ordered using Test No. 070327. Trough levels should be ordered using Test No. 070328. Please label tubes appropriately as “peak” and “trough.”
Z51.81 is a billable diagnosis code used to specify a medical diagnosis of encounter for therapeutic drug level monitoring. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2024 through September 30, 2025.
2 sie 2024 · Vancomycin is a glycopeptide antibiotic administered intravenously for treatment of patients with suspected or proven invasive gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).
